Pasithea Therapeutics Corp. (KTTA)
| Market Cap | $16.86M-30.5% |
| Revenue (ttm) | n/a |
| Net Income | -$24.83M |
| EPS | -$1.59 |
| Shares Out | 36.75M |
| PE Ratio | n/a |
| Forward PE | -1.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,422 |
| Open | $0.45 |
| Previous Close | $0.43 |
| Day's Range | $0.45 - $0.47 |
| 52-Week Range | $0.28 - $2.06 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | $4.00(+772.03%) |
| Earnings Date | n/a |
About KTTA
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KTTA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KTTA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KTTA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KTTA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KTTA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KTTA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from KTTA’s recent data — informational, not investment advice
